Adult Dosing
Intestinal amebiasis
- Usual dose: 25 to 35 mg/kg/day PO tid with food x 5-10 days
Management of hepatic coma
- Usual dose: 4 g/day PO in divided doses x 5-6 days
Pediatric Dosing
Intestinal amebiasis
- Usual dose: 25 to 35 mg/kg/day PO tid with food x 5-10 days
- Clostridium difficile associated diarrhea which may vary in severity from mild to fatal colitis, has been reported with use of all antibiotics. Maintain appropriate fluid and electrolyte levels, protein supplementation, along with antibiotics for C. difficile as needed
- To reduce the development of drug-resistant bacteria, use only to treat infections proven or strongly suspected to be caused by susceptible bacteria. Obtain susceptibility tests before starting therapy
- Overgrowth of nonsusceptible organisms including fungi may occur; monitor patients carefully and take appropriate measures
- Monitor patient for signs of anaphylaxis or allergic reactions
- Has the potential to cause nephrotoxic, ototoxic, and probably neuromuscular blocking effects, worsening of myasthenia gravis or parkinsonism have occurred in patients with muscular disorders
- Not effective in extraintestinal amebiasis
Cautions: Use cautiously in:
- Renal impairment
- Inflammatory bowel disease
- Ulcerative lesions of the bowel
- Ulcerative colitis
- Dehydration
- Electrolyte abnormalities
- Concomitant nephrotoxic agents
- Concomitant ototoxic agents
- Concomitant neurotoxic agents
- Impaired vestibular function
- Impaired auditory function
- Neuromuscular disease
- Prolonged use
- Neonates
- Infants
- Geriatrics
Pregnancy Category:C
Breastfeeding: Probably safe; Manufacturer advises caution
